EA200970021A1 - COMBINED PREPARATIONS CONTAINING SLV308 AND L-DOPA - Google Patents

COMBINED PREPARATIONS CONTAINING SLV308 AND L-DOPA

Info

Publication number
EA200970021A1
EA200970021A1 EA200970021A EA200970021A EA200970021A1 EA 200970021 A1 EA200970021 A1 EA 200970021A1 EA 200970021 A EA200970021 A EA 200970021A EA 200970021 A EA200970021 A EA 200970021A EA 200970021 A1 EA200970021 A1 EA 200970021A1
Authority
EA
Eurasian Patent Office
Prior art keywords
slv308
dopa
preparations containing
combined preparations
simultaneous
Prior art date
Application number
EA200970021A
Other languages
Russian (ru)
Other versions
EA015073B1 (en
Inventor
Эндрю К. Маккрири
Гюстаф Й.М. Ван Схарренбург
Мартинус Т.М. Тюлп
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200970021A1 publication Critical patent/EA200970021A1/en
Publication of EA015073B1 publication Critical patent/EA015073B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к применению комбинированного препарата SLV308 или его N-оксида, или фармакологически приемлемых солей этих соединений (I), (II), и L-DOPA, для одновременного, отдельного или последовательного применения для лечения нарушений, требующих восстановления дофаминергической функции, в частности болезни Паркинсона и синдрома усталых ног.The invention relates to the use of a combined preparation of SLV308 or its N-oxide, or pharmacologically acceptable salts of these compounds (I), (II), and L-DOPA, for simultaneous, separate or sequential use for the treatment of disorders requiring restoration of dopaminergic function, in particular Parkinson's disease and tired legs syndrome.

EA200970021A 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a l-dopa EA015073B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405106P 2006-06-16 2006-06-16
EP06115583 2006-06-16
PCT/EP2007/055955 WO2007144421A1 (en) 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a l-dopa

Publications (2)

Publication Number Publication Date
EA200970021A1 true EA200970021A1 (en) 2009-06-30
EA015073B1 EA015073B1 (en) 2011-04-29

Family

ID=38434785

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970021A EA015073B1 (en) 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a l-dopa

Country Status (10)

Country Link
EP (1) EP2035002A1 (en)
JP (1) JP2009539941A (en)
KR (1) KR20090031908A (en)
AU (1) AU2007259255A1 (en)
CA (1) CA2654719A1 (en)
EA (1) EA015073B1 (en)
IL (1) IL195532A0 (en)
MY (1) MY148457A (en)
NO (1) NO20090164L (en)
WO (1) WO2007144421A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7596407B2 (en) * 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
KR20070059161A (en) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
RU2394821C2 (en) * 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-oxides as prodrug of piperazine and piperidine derivatives

Also Published As

Publication number Publication date
EA015073B1 (en) 2011-04-29
CA2654719A1 (en) 2007-12-21
MY148457A (en) 2013-04-30
WO2007144421A1 (en) 2007-12-21
JP2009539941A (en) 2009-11-19
KR20090031908A (en) 2009-03-30
AU2007259255A1 (en) 2007-12-21
NO20090164L (en) 2009-01-14
EP2035002A1 (en) 2009-03-18
IL195532A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
LU93321I2 (en) IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EA200971107A1 (en) CATECHOLAMINE DERIVATIVES, USEFUL FOR THE TREATMENT OF PARKINSON'S Disease
NO20084256L (en) DPP IV inhibitor formulations
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
EA200870193A1 (en) CYTOTOXIC AGENTS, INCLUDING NEW TOMAMYCIN DERIVATIVES, AND THEIR THERAPEUTIC APPLICATION
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
BRPI0611705A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and use of compound
DE60332629D1 (en) PHENYL- (4- (3-phenyl-1H-pyrazol-4-yl) -pyrimidin-2-yl) amine derivatives
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
BRPI0416628A (en) use of organic compounds
EA200801826A1 (en) DEUTERATED CATECHOLAMINE DERIVATIVES AND MEDICINES CONTAINING INDICATED COMPOUNDS
EA201170527A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING BORONIC ACID COMPOUNDS
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
TW200612922A (en) Inhibitors of hsp90
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
ATE499939T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERIN POLYMORPHO A
EA200970022A1 (en) COMBINED PREPARATIONS CONTAINING BIFEPRUNOX AND L-DOSP
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
CL2009001267A1 (en) Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.
CL2007000789A1 (en) Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.
EA201070195A1 (en) DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
DK1786442T3 (en) Treatment of neurodegenerative diseases using DEGS inhibitors
EA200970021A1 (en) COMBINED PREPARATIONS CONTAINING SLV308 AND L-DOPA
ITMI20060712A1 (en) USE OF AMINAHTONE FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF ARTERIOPATHY
WO2009137436A3 (en) Peptide conjugates

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU